Disclosed is an antibody or functional fragment thereof that binds human platelet derived growth factor receptor-beta antibodies (PDGFRbeta), comprising a CDRH1 having the sequence SYAIS (SEQ ID NO:20), a CDRH2 having the sequence RIIPILGIANYAQKFQG (SEQ ID NO:22), a CDRH3 having the sequence DMGSRNYYYFY (SEQ ID NO:24), a CDRL1 having the sequence RASQSVGRYLA (SEQ ID NO:28), a CDRL2 having the sequence GASNRAT (SEQ ID NO:30), and a CDRL3 having the sequence QQRSNWPLT (SEQ ID NO:32). The antibody is suitable for the treatment of cancer including ovarian, non-small-cell lung cancer (NSCLC), pancreatic, colon, and giloblastoma.